Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012)

Bristol Myers Squibb (CELG-RI) posted quarterly Amortizatization of Intangibles of $102.0 million for Q2 2012, up 7.37% YoY from $95.0 million in Q3 2011, and up 0.99% sequentially from $101.0 million in Q1 2012.

Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends

Bristol Myers Squibb has disclosed Amortizatization of Intangibles across 4 years of filings, most recently posting $102.0 million for Q2 2012.

  • In Q2 2012, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million; the TTM figure through Jun 2012 stood at $388.0 million (up 26.38% YoY), while the FY2011 annual figure was $353.0 million, up 30.26% from the prior year.
  • Amortizatization of Intangibles rose to $102.0 million in Q2 2012, from $101.0 million in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for CELG-RI reached as high as $102.0 million in Q2 2012 and fell as low as $59.0 million in Q3 2009.
  • The 4-year median for Amortizatization of Intangibles is $75.5 million (2009), against an average of $80.3 million.
  • Annual changes were most pronounced in 2010 — Amortizatization of Intangibles dropped 6.41% — and 2011, when it jumped 41.79%.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $78.0 million in 2009, then retreated by 6.41% to $73.0 million in 2010, then grew by 26.03% to $92.0 million in 2011, then rose by 10.87% to $102.0 million in 2012.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $102.0 million, $101.0 million, and $92.0 million for Q2 2012, Q1 2012, and Q4 2011 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. of Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 1.70 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 931.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 596.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2012 102.00 Mn
Jun 30, 2012 102.00 Mn
Mar 31, 2012 101.00 Mn
Mar 31, 2012 101.00 Mn
Dec 31, 2011 92.00 Mn
Dec 31, 2011 92.00 Mn
Sep 30, 2011 93.00 Mn
Sep 30, 2011 93.00 Mn
Jun 30, 2011 95.00 Mn
Jun 30, 2011 95.00 Mn
Mar 31, 2011 73.00 Mn
Mar 31, 2011 73.00 Mn
Dec 31, 2010 73.00 Mn
Dec 31, 2010 73.00 Mn
Sep 30, 2010 66.00 Mn
Sep 30, 2010 66.00 Mn
Jun 30, 2010 67.00 Mn
Jun 30, 2010 67.00 Mn
Mar 31, 2010 65.00 Mn
Mar 31, 2010 65.00 Mn